The 10-year health impact, economic impact, and return on investment of the South African molecular diagnostics programme for HIV, Tuberculosis and SARS-CoV-2

- 4
- 5 Brooke E. Nichols^{1,2}*, Alexandra de Nooy², Naseem Cassim^{3,4}, Lucia Hans^{3,4,5}, Manuel Pedro da Sil-
- ⁶ va^{3,4}, Kamy Chetty⁴, Kyra H. Grantz^{2,3}, Alvin X. Han⁶, Andrew N. Phillips⁷, Lise Jamieson^{8,9}, Lesley
- 7 E. Scott³, Wendy S. Stevens^{3,4*}
- 8
- ⁹ ¹ Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC,
- 10 University of Amsterdam, Amsterdam, Netherlands
- ¹¹ ² FIND, Geneva, Switzerland
- ³ Wits Diagnostic Innovation Hub, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,
 South Africa
- ⁴ National Health Laboratory Service (NHLS), Johannesburg, South Africa
- ⁵ Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of Witwaters rand, Johannesburg, South Africa
- ⁶ Department of Medical Microbiology, Amsterdam University Medical Center, Amsterdam, Netherlands
- ⁷ Institute for Global Health, University College London, London, UK
- ⁸ Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johan nesburg, South Africa
- 21 ⁹ The South African Department of Science and Innovation/National Research Foundation Centre of Excellence in Epidemio-
- 22 logical Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa
- 23
- 24
- 25 *Correspondence: brooke.nichols@finddx.org, wendy.stevens@wits.ac.za
- 26
- Keywords: molecular diagnostics, tuberculosis, HIV, SARS-COV-2, return on investment, impact
- 28
- 29
- 30
- 31
- 51
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40 41
 - L
- 42
- 43

44 ABSTRACT

45

To ensure there is adequate investment into diagnostics, an understanding of the magnitude of 46 impact and return on investment is necessary. We therefore sought to understand the health 47 and economic impacts of the molecular diagnostic programme in South Africa, to deepen the 48 understanding on the broad value of diagnostics and guide future healthcare investments. We 49 calculated the 10-year (where data were available) total cost and DALYs averted associated 50 with molecular diagnosis of molecular TB testing (2013-2022), HIV viral load monitoring 51 (2013-2022), early infant diagnosis of HIV infection (2013-2022), and SARS-CoV-2 testing 52 (2020-2022). We then calculated the economic value associated with those health gains and 53 subsequent return on investment. Since the inception of the molecular diagnostics programme 54 in South Africa, 3,035,782 DALYs have been averted as a direct consequence of this pro-55 gramme. This has generated an estimated \$20.5 billion in economic value due to these health 56 gains. The return on investment varied by specific diagnostic test (19.0 for tuberculosis, 1.4 57 for HIV viral load testing, 64.8 for early infant diagnosis of HIV, and 2.5 for SARS-CoV-2), 58 for an average of 9.9 for the entire molecular diagnostics programme between 2013 and 59 2022- or \$9.9 of value for each \$1 invested. The molecular diagnostics programme in South 60 Africa generated a significant amount of health gains and economic value associated with 61 these health gains, and the return-on-investment rivals other high-impact public health inter-62 ventions such as childhood vaccination. Consequently, the molecular diagnostics programme 63 in South Africa is highly impactful, and will continue to be an excellent investment of South 64 African public health expenditure. 65

- 66
- 67

69

- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77

78 INTRODUCTION

79

Diagnostics play a vital role in ensuring quality health care at an individual level - through 80 disease diagnosis and screening as well as condition and treatment monitoring- and at the 81 82 global, national, or regional level through population disease surveillance (1). However, the importance of diagnostics is frequently overlooked, resulting in underfunded or un-83 der-resourced programmes (2). It is estimated that approximately 47% of the global popula-84 tion have limited (if any) access to diagnostics, with alarming disparity between the Global 85 North and the Global South (2). Further, in comparison with other key healthcare elements, 86 like medicine, investment in diagnostics has historically been limited (3). This is concerning 87 given the direct connection between diagnosis and treatment- and has resulted in significant 88 empiric treatment across the disease spectrum, resulting in over-, under-, or incorrect treat-89 ment (3). Additionally, although there is notable evidence of the substantial diagnostic gap in 90 many low- and middle-income countries (LMICs) - particularly for key disease areas like 91 HIV, tuberculosis (TB) and diabetes - there is little high-level literature which demonstrates 92 the direct and long-term health and economic impacts of strong and well-distributed public 93 health diagnostic programmes (4). This lack of evidence has limited the broad country-level 94 investments in diagnostics needed to ensure quality health care for all. 95

96

In terms of diagnostic access, South Africa is a leader within the South African Development 97 Community (SADC) region of sub-Saharan Africa. The country's National Health Laborato-98 ry Service (NHLS) has a network of centralised molecular laboratory facilities and a daily 99 specimen transportation and results delivery system. There is cover at all public healthcare 100 facilities (PHCs) across the country, to provide diagnostic service support to ~85% of the to-101 tal population and 100% of the public sector (5-7). Further, the NHLS conducts millions of 102 tests (both molecular and other) each year across a range of diseases, with nearly 107 million 103 tests being performed in 2021-2022 (8). Of these, approximately 10 million (9.4%) were mo-104 lecular tests performed by the NHLS that support the long-standing HIV and TB treatment 105 programmes and more recently the severe acute respiratory syndrome coronavirus 2 106 (SARS-CoV-2) programme (8,9). These include HIV viral load testing, early infant diagnosis 107 (EID) for HIV infection, tuberculosis diagnosis, as well as SARS-CoV-2 diagnosis. Over the 108 last decade, molecular diagnostics have been introduced to each programme at different time 109 points. In 2004, molecular diagnostics were introduced for viral load monitoring of people 110 living with HIV on antiretroviral treatment. In 2011, the molecular diagnostics programme 111 for TB was introduced, replacing the standard of care for TB diagnosis at the time- the less 112 accurate smear microscopy. The molecular diagnosis programme expanded to include early 113 infant diagnosis of HIV in 2013. All these molecular platforms were leveraged for the diag-114 nosis of SARS-CoV-2 infection in 2020. 115

116

To ensure there is ongoing adequate and sustainable investment in diagnostics, an understanding of the magnitude of impact and return on investment is necessary. We, therefore, investigated the ten-year health and economic impacts of the public health molecular diag-

nostic programme in South Africa to deepen the understanding on the broad value of diagnostics to guide future healthcare investments.

122 METHODS

123 Health impact

The health impact, in terms of disability adjusted life years (DALYs), of each of the molecu-124 lar diagnostic tools was calculated separately (Table 1). The health impact for TB, HIV viral 125load, early infant diagnosis of HIV, and SARS-CoV-2 molecular testing were all sourced 126 from the literature or updated from existing models in the literature to understand both direct 127 clinical benefit of diagnosis and the extended benefits that diagnostic testing or monitoring 128 129 associated with a potential reduction in disease transmission can have. Impact can result from multiple tests of a single individual (e.g. a TB diagnosis and a viral load monitoring test), and 130 these benefits are assumed to be additive. 131

132

133 Diagnosis of tuberculosis

The total number of TB tests conducted and number of positive diagnoses through the mo-134 lecular diagnostics programme in South Africa was sourced from the literature(10). We 135 compared the total net impact of the molecular TB programme as well as the incremental 136 impact compared to if the sputum smear microscopy (SSM) programme had continued as it 137 was in 2010. For the counterfactual SSM programme, we assumed that 1.329 million tests per 138 year would be conducted from 2013-2022 (the same number of tests conducted in 2010 when 139 the SSM diagnostic programme was at capacity)(11). We then assumed a constant 10% prev-140alence of TB among those tested, and a 68% test sensitivity, and a 98% test specificity of 141 sputum smear microscopy (11). The sensitivity and specificity of Xpert MTB/Rif (12) was 142 assumed to be 85% and 98% respectively, and the sensitivity and specificity of Xpert 143 MTB/Rif Ultra (13), was assumed to be 91% and 99% respectively(14). For the total impact 144 of the programme, we multiplied the number of DALYs averted per correct positive TB di-145 agnosis (assumed to be 1 DALY per diagnosis (15)) by the number of correct TB diagnoses 146reported over time(10) (adjusting for test specificity). The benefits of the molecular pro-147 gramme are results of the improved accuracy of molecular diagnostics compared to smear 148microscopy for TB diagnosis. 149

150

151 HIV viral load monitoring

The HIV Synthesis model, an individual-based stochastic simulation model that includes HIV 152 transmission, progression, HIV-related treatment, and prevention interventions, was used to 153 estimate the DALYs associated with a viral load test (16,17). Two scenarios were run to tease 154 out the incremental benefit of viral load testing: 1) no viral load testing for three years, fol-155 lowed by fully implemented viral load testing, and 2) fully implemented viral load testing 156 over 10 years. The difference in DALYs between the two scenarios provides an indication of 157 the DALYs averted because of viral load testing alone. To account for stochasticity, the mod-158 el was run 300 times to produce an estimated average of 1250 DALYs averted per 3 months, 159in the context of an adult population of 10 million with 207,000 viral load tests done per 3 160

months compared to when no viral load tests were done. This resulted in 0.006 DALYs
 averted for each viral load conducted.

163

We then multiplied the number of viral load tests by the number of DALYs averted per viral load conducted across the lifespan of the NHLS molecular diagnostics programme. Given that we calculated the impact per viral load test conducted (rather than per elevated viral load result), specific test accuracy parameters were not taken into account.

- 168
- 169 *HIV early infant diagnosis* (EID)

A model of quality assurance systems for HIV EID estimated the DALYs associated with false negative test results with and without these systems for five countries(18). This study indicated that the DALYs associated with an undiagnosed case of HIV among infants was 24.6 in South Africa. We then multiplied the number of DALYs averted by the number of infants correctly diagnosed with HIV by year as reported in the literature(19) (adjusting for test specificity). The sensitivity of HIV EID is assumed to be 99.3% and specificity 99.5% (20), and a second test is required for confirmation.

177

178 Diagnosis of SARS-CoV-2

We used results from the Propelling Action for Testing and Treating (PATAT) simulation 179 model of SARS-CoV-2 transmission to estimate the DALYs averted per SARS-CoV-2 diag-180 nostic test used in countries most similar to South Africa in terms of population demography 181 and household size (21,22). The impact of testing was primarily due to the reduction in the 182 number of onward infections following isolation of positive cases, rather than any specific 183 clinical impact. Individuals were assumed to reduce their number of community contacts by 184 50% on average after receiving a positive diagnosis but were not assumed to be able to effec-185 tively isolate from household members. Given that the relative impact of testing for 186 187 SARS-CoV-2 is dependent on several parameters, we averaged the impact across effective reproductive numbers of SARS-CoV-2 from 1.2-2.0, a testing rate of 100 tests per 100,000 188 per year, and minimal vaccine coverage. This resulted in 0.0651 DALYs averted per correct 189 positive test result (adjusted for test specificity). The sensitivity of molecular SARS-CoV-2 190 testing was assumed to be 99% and specificity 97% (23). 191

192

193 Economic impact of health gains and return on investment (ROI)

194 The total number of DALYs per health area were calculated per year and multiplied by the GDP per capita per respective year to calculate the economic impact of the molecular diag-195 nostics programme. Results are reported for each diagnostic test, and for the entire pro-196 gramme (Table 1). No DALYs are averted for false positive results at the end of a diagnostic 197 algorithm, calculated using the average expected incidence of infection for each health area 198 and the specificity of the test or test algorithm. All health benefits and related economic gains 199 are expressed in terms of net present value of these gains. The health benefits (DALYs 200 averted) of a TB molecular diagnostic are expected to occur over a lifetime after the average 201 age of active TB disease, the benefits of HIV viral load testing were calculated over a 202

ten-year period (discounted at 3% annually), early infant diagnosis over a lifetime (discount-

ed at 3% annually), and SARS-CoV-2 testing over 1 year (as such, not discounted).

205

Return on investment was calculated as the total economic impact per diagnostic tool divided 206 by the total cost of all diagnostic tests required to generate that impact (including both "posi-207 tive" and "negative" tests). The total number of tests per programme, across the respective 208 time periods considered, were taken from the literature for TB, HIV viral load, SARS-CoV-2, 209 and EID (10,19,24-26). To calculate the number of HIV EID tests conducted on average for 210 2020-2022, we used the number of live births to women living with HIV in 2021 (~275 527), 211 the EID testing algorithm in South Africa and the coverage of testing at each part of the algo-212 rithm (averaged between NICD and DHIS sources). Given the relative overcounting of in-213 fants diagnosed with HIV reported in the literature(19), we also adjusted the numbers of posi-214 tive infants reported in 2013-2019 down to reflect this overcounting. We also adjusted for the 215 neonatal mortality rate in South Africa for number of infants expected to be tested at 10 216 weeks, and the number of infants testing positive who would not need to be retested (27). 217 218

- The total costs were calculated as the 2022 test price per test in South African Rands (ZAR), 219 converted to United States Dollar (USD) using average 2022 conversion rate (16.37 ZAR to 220 1USD (28)), and multiplying each respective test cost by the total number of tests of that type 221 conducted per year since the inception of the molecular diagnostic programme. "Deadweight" 222 costs have been removed from the ROI analysis for TB diagnosis by using the appropriate 223 incremental gains of the molecular programme (e.g. removing the costs associated with the 224 counterfactual of keeping the sputum smear microscopy programme running at the same 225 scale as when the molecular programme had been introduced). The additional costs incurred 226 associated with false positive test results for TB and EID were calculated using prevalence of 227 infection and test specificity of the testing algorithm. These additional costs included those 228 229 for unnecessary treatment of drug sensitive TB disease, US\$ 112.70 (29), and unnecessary lifetime ART treatment cost for an misdiagnosed with HIV, US\$ 6,115 (discounted at 3% per 230 year, assuming a life expectancy of 63.8 years) (18). 231
- 232

233	Table 1. The cost per test and DALYs assumed per test or diagnosis as noted per disease area supported
234	by the molecular diagnostics programme in South Africa

Test con-	Lab price	Total cost per	Source	DALYs avert-	Source
ducted	per test	test (including		ed per diagno-	
	(2022	staff and con-		sis or per test	
	USD)	sumables for		conducted	
		specimen col-			
		lection) (2022			
		USD)			
TB molecular	US\$ 14.01	US\$ 17.41	NHLS, (29)	1 per diagnosis	(15,29,30)
diagnosis					
HIV viral load	US\$ 24.00	US\$ 28.10	NHLS, (29,30)	0.006 per test	(16,17,29–31)

				conducted	
Early infant	US\$ 27.73	US\$ 28.9	NHLS, (29,30)	24.6 per diag-	(18,29,30)
diagnosis of				nosis	
HIV					
SARS-CoV-2	US\$ 24.56	US\$ 32.84	NHLS, (29)	0.0651 per pos-	(21,22,29)
molecular				itive diagnosis	
diagnosis					
Sputum smear	US\$ 1.88	US\$ 4.06	(29)	1 per diagnosis	(15,29)
microscopy*					

235

251

*Only used to calculate the counterfactual of the TB molecular diagnosis programme

236


237 **Ethics**

Solely aggregate data from previously published manuscripts was used for this analysis. (10,19,24,25). The data are available *open access* in each publication. Any missing data points were imputed rather than extracted from raw data.

241 **RESULTS**

242 Health Impact

Since the inception of the molecular diagnostics programme in South Africa, 3,035,782 243 DALYs have been averted as a direct consequence of this programme. This includes 961,499 244 incremental DALYs averted due to the diagnosis of TB (2013-2022) (incremental to a con-245 tinued smear microscopy programme, adjusting for false positive test results), 272,009 avert-246 ed due to HIV viral load tests (2013-2022), 1,700,208 due to early infant diagnosis 247 248 (2013-2022), and 102,066 DALYs averted due to molecular SARS-CoV-2 testing (2020-2022). Figure one highlights the relative impact per year that each of the diagnostics 249 has demonstrated. 250



- 252
- 232

253

254


Figure 1. The annual DALYs averted of South Africa's public sector molecular diagnostics programme for HIV,
 TB and SARS-CoV-2 from 2013-2022

257

258 Economic impact of health gains

The total economic value of the molecular diagnostics programme due to health gains over the ten-year period was US\$ 20.5 billion. This includes US\$ 6.4 billion in economic value associated with improved health related to TB diagnosis (2013-2022), US\$ 1.8 billion for HIV viral load testing (2013-2022), US\$ 11.6 billion for HIV early infant diagnosis (2013-2022), and \$0.7 billion for SARS-CoV-2 testing (2020-2022) (Figure 2).





265

Figure 2. Annual economic value (in 2022 USD) associated with the health gains of the molecular diagnostics programme for HIV, TB and SARS-CoV-2 from 2013-2022

268

269 Return on investment

The molecular TB diagnostics programme has cost an estimated US\$ 418 million over 10 270 years (for all TB diagnostics conducted plus costs associated with false positive test results), 271 while our counterfactual was assumed to cost \$81 million over the same period (for diagnos-272 tics plus costs associated with false positive results), for an incremental cost of USD\$337 273 million of the molecular TB diagnostics programme. The total incremental economic value of 274 health gains associated with TB molecular diagnosis divided by the total incremental cost of 275 the molecular TB diagnostics programme resulted in a return on investment of 19.0- or 276 US\$ 19.0 of economic value for each US\$ 1 invested in diagnosis. The return on investment 277 for HIV viral load was 1.4, for HIV early infant diagnosis was 64.8, and for SARS-CoV-2 278

diagnosis was 2.5. Averaged across the whole molecular diagnostics programme, the average

return on investment was 9.9 - or US\$ 9.9 of economic gain related to improved health for

each US\$ 1 invested in diagnostics.

- 282
- Table 2. The return on investment of the molecular diagnostics programme in South Africa, as expressed by the
- total economic value of the health returns divided by the costs of conducting those tests across all years consid-
- ered in this analysis

Test conducted	Economic value of health gains (2022 USD)	Total cost of imple- mentation (2022 USD)	Return on invest- ment
TB molecular diagnosis*	US\$ 6.4 billion	US\$ 337 million**	19.0
HIV viral load	US\$ 1.7 billion	US\$ 1.27 billion	1.4
Early infant diagnosis of HIV	US\$ 6.1 billion	US\$ 179 million**	64.8
SARS-CoV-2 molecular diagnosis	US\$ 0.6 billion	US\$ 273 million	2.5
Total	US\$ 20.5 billion	US\$ 2.1 billion	9.9

286 287 *Incremental benefit compared to a counterfactual of a smear microscopy programme

**Including healthcare costs associated with false positive test results

288 **DISCUSSION**

289

Generally, molecular testing has multiple roles in disease management, including diagnosis, 290 monitoring response to treatment and guiding decisions on appropriate management (e.g. in-291 dications for HIV drug resistance tests) (9). Further, as compared to other diagnostic counter-292 parts (like TB culture), molecular tests are frequently able to return accurate results more rap-293 idly, and hence allow for action to be taken at an earlier stage (9). Thus, molecular testing, if 294 well-implemented, has the potential to greatly improve patient outcomes. This has been 295 shown by the public sector molecular diagnostics programme in South Africa that generated a 296 significant amount of health gains and economic value associated with these health gains. The 297 return on investment was ≥1.4 for all individual tests, as high as 64.8 and 9.9 on average-298 suggesting excellent value for money across all molecular tests. These levels of return on in-299 vestments for some tests rival childhood vaccination programmes (ROI 16)- often considered 300 one of the most valuable public health interventions (32,33). While the ROI value for each of 301 the individual types of molecular tests varied greatly, each still resulted in a positive impact 302 on the South African healthcare system given that all tests had at least a full ROI. 303

304

Comparing to other public health tools such as vaccines and therapeutics, for each specific disease area is useful to understand the relative role of diagnostics as part of a public health programme. For SARS-CoV-2, the ROI of vaccination has not been estimated for South Africa, but in New York City was estimated to be 10 to 1(34). If adjusting this estimate for the GDP per capita in South Africa, and the smaller proportion of people at risk for severe disease

and death in South Africa (due to demographic differences), the ROI for SARS-CoV-2 vac-310 cines in South Africa might approach the value of diagnostics in South Africa. ROIs for spe-311 cific therapeutics for SARS-CoV-2 in South Africa have not been calculated. Therapeutics 312 such as paxlovid, however, have not been available in South Africa. For both TB and HIV, 313 the return on investment for investments into vaccines has been effectively 0 (or negative) 314 given that there are no vaccines available for HIV, and no effective vaccines for adults for TB 315 (with the BCG vaccine for TB protective for <5-year-olds only). For HIV, the UNAIDS 316 "Fast-Track" strategy which focuses on investments in expanding HIV service coverage (as 317 opposed to maintaining constant coverage) estimates an approximate return on investment of 318 6.46 to 1 for Southern Africa (35,36). This contextualizes that viral load testing is comple-319 mentary to a broader package of HIV-related services, with an ROI of 2, and that early infant 320 diagnosis remains to have an extraordinarily high ROI. With respect to TB, there also exists a 321 set of services which together have resulted in an estimated drop of more than 50% in the in-322 cidence rate between 2011 and 2022 (37). While it is difficult to quantify exactly how much 323 each particular service (e.g. the increase in TB diagnostic capacity and accessibility, increased 324 TB treatment options and the impact of improved HIV services) has contributed towards re-325 duced incidence, the introduction of Xpert MTB/Rif and Ultra and the scale-up of the molec-326 ular testing programme has clearly contributed. Similarly in terms of investment, while there 327 is no specific literature available on the return-on-investment of TB diagnostics, studies have 328 shown that TB prevention and care yields a ROI of 43- implicitly including diagnosis-329 whereas we have estimated the ROI of diagnosis aspect to prevention and care to be 19.0 (38). 330 331

These values represent one consistent methodological way to calculate impact, economic val-332 ue, and ROI. There are several changes in the underlying assumptions that might influence the 333 direction of these values in both directions. Firstly, the average GDP per capita in South Afri-334 ca may not reflect the burden of disease where the health gains occurred for each respective 335 336 disease (e.g. slightly lower burden of disease among higher household social economic index score for tuberculosis infection) (39). If including these differences, the economic gains might 337 be slightly overstated where the benefits occurred amongst individuals with lower annual 338 GDP. We did not, however, want to weight the economic value of health differently among 339 the South African population. In the other direction, within the scope of this analysis, we have 340 only calculated the economic value of the health gains associated with molecular diagnostics 341 rather than the *total* economic benefit. The total economic benefit likely far exceeds what we 342 have estimated here- for example, the benefits associated with being able to return to work 343 after a negative SARS-CoV-2 test during the pandemic or benefits associated with the re-344 duced frequency of healthcare clinic visits required after a suppressed viral load test- reducing 345 costs to individuals on antiretroviral treatment and possibly increasing economic activity due 346 to fewer days spent seeking care. Estimating the total value was outside the scope of this 347 analysis. 348

349

There were several limitations to our analysis. First, we did not include the value related to drug susceptibility testing (DST) for tuberculosis given the paucity of literature on the

DALYs associated with TB resistance testing. If we had included that, the likely value and 352 impact of the molecular diagnostic programme would have only increased, especially since 353 the diagnosis of rifampicin resistant TB is provided simultaneously with the molecular diag-354 nosis of TB. Second, for the incremental impact of the TB molecular diagnostics programme, 355 we assumed that the size of the smear microscopy programme would have held constant in 356 size from 2010 onwards. An expansion of this programme would have generated more health 357 effects and related economic value of health gains, resulting in a diminished incremental ben-358 efit of the molecular programme. We made this assumption, however, given that the micros-359 copy programme was already at capacity in 2010. Third, for the HIV viral load DALY calcu-360 lations, it was assumed that individuals would be on a dolutegravir-based first line antiretro-361 viral treatment regimen. The DALYs per viral load would have likely been greater in 362 pre-dolutegravir era, given that previous regimens were slightly less effective. This would 363 have resulted in a slight underestimate of the benefit of viral load testing before the introduc-364 tion of dolutegravir-based first-line antiretroviral treatment regimens- but do reflect the likely 365 benefit moving forward. Fourth, while we have presented here the net present benefits of the 366 molecular diagnostics programme, the time horizon of the economic benefit associated with 367 health gains differ between diseases. Finally, we did not consider the impact of potential addi-368 tional costs incurred as a result of test sensitivity given the uncertainty around the costs that 369 may occur as a consequence (e.g. false negative tests). Individuals who receive a false nega-370 tive result may need to seek care again (or multiple times) to receive a correct diagnosis, in-371 curring additional costs (most likely with TB testing, less so for SARS-CoV-2 given the short 372 duration of infection). These individuals may also transmit infection if they are diagnosed 373 negative (for TB, SARS-CoV-2, possibly for viral load if individuals think they are sup-374 pressed; not likely for EID). It is unlikely, however, that these tests will influence our results 375 significantly, and the relative test sensitivity of molecular diagnostics is relatively high com-376 pared to other available diagnostics. 377

378 CONCLUSIONS

379 In conclusion, the molecular diagnostics programme in South Africa is highly impactful, and will continue to be an excellent investment of South African health expenditure. The value 380 and return on investment of these diagnostic tools is in line with other highly impactful public 381 health interventions and should continue to be valued as such. Into the future, molecular di-382 agnostics are likely to play a more significant role in the monitoring and control of existing 383 diseases (other than those described here) and, as seen for SARS-CoV-2, may be the first 384 point of call for the diagnosis of and surveillance of future pandemics given their relative 385 ease of development and implementation into existing systems. 386

387 388

389

Author Contributions: Conceptualization, BEN, LES, WSS; methodology, BEN; formal
 analysis, BEN, KHG, AXH, ANP, LJ; data curation, AdN, NC, LH, MPdS, KC, LES, WSS.;
 writing—original draft preparation, BEN AdN; writing—review and editing, (NC, LH, MPdS,

KC, KHG, AXH, ANP, LJ, LES, WSS); All authors have read and agreed to the published
 version of the manuscript.

³⁹⁵ Funding: Funding was received from the Bill and Melinda Gates Foundation, the South Af-

³⁹⁶ rican Medical Research Council and the National Institutes of Health. The funder had no role

in study design, data collection and analysis, decision to publish, or preparation of the manu-script.

399

400 Institutional Review Board Statement: Not applicable

401 Informed Consent Statement: Not applicable

402
403 Data Availability Statement: The data are available *open access* in each relevant publication.
404 Any missing data points were imputed rather than from raw data.

405 **Conflicts of Interest:** The authors have no conflict of interest to declare.

406 **REFERENCES**

407

4081.African Region - World Health Organization (W.H.O). REGIONAL STRATEGY ON409DIAGNOSTIC AND LABORATORY SERVICES AND SYSTEMS, 2023–2032 FOR THE410WHO AFRICAN REGION. Gaborone; 2023 Jul.

- 411 2. Fleming KA, Horton S, Wilson ML, Atun R, DeStigter K, Flanigan J, et al. The Lancet
 412 Commission on diagnostics: transforming access to diagnostics. The Lancet [Internet].
 413 2021 Nov 27 [cited 2024 Feb 7];398(10315):1997–2050. Available from:
 414 http://www.thelancet.com/article/S0140673621006735/fulltext
- 4153.Pai M, Walia K, Boehme CC. Essential medicines and essential diagnostics: a package416deal. Lancet Public Health [Internet]. 2019 Oct 1 [cited 2024 Feb 7];4(10):e492. Available417from: http://www.thelancet.com/article/S2468266719301653/fulltext
- 4184.Boehme C, Hannay E, Pai M. Promoting diagnostics as a global good. Nature Medicine4192021 27:3 [Internet]. 2021 Mar 15 [cited 2024 Feb 7];27(3):367–8. Available from:420https://www.nature.com/articles/s41591-020-01215-3
- 4215.Girdwood SJ, Crompton T, Cassim N, Olsen F, Sejake P, Diallo K, et al. Optimising422courier specimen collection time improves patient access to HIV viral load testing in423South Africa. Afr J Lab Med [Internet]. 2022 [cited 2024 Feb 9];11(1). Available from:424https://pubmed.ncbi.nlm.nih.gov/36337769/
- 4256.Girdwood SJ, Crompton T, Sharma M, Dorward J, Garrett N, Drain PK, et al.426Cost-effectiveness of adoption strategies for point of care HIV viral load monitoring in427South Africa. EClinicalMedicine [Internet]. 2020 Nov 1 [cited 2024 Feb 9];28. Available428from: https://pubmed.ncbi.nlm.nih.gov/33294817/

7. 429 National Health Laboratory Service. Annual Report 2022-2023 [Internet]. Johannesburg; 2023 [cited 2024 Mar 18]. Available from: 430 https://www.nhls.ac.za/wp-content/uploads/2023/11/241023-NHLS-Annual_Report.pdf 431 8. National health laboratory Service (NHLS). NHLS Annual Report 2021-2022 [Internet]. 432 2022 [cited 2024 Available Mar 4]. from: 433 https://www.nhls.ac.za/wp-content/uploads/2022/10/NHLS_AR_2022_web_version.pdf 434

435	9.	Messacar K, Parker SK, Todd JK, Dominguez SR. Implementation of rapid molecular
436	,	infectious disease diagnostics: The role of diagnostic and antimicrobial stewardship. J
437		Clin Microbiol [Internet]. 2017 Mar 1 [cited 2024 Feb 7];55(3):715–23. Available from:
438		https://journals.asm.org/doi/10.1128/jcm.02264-16
439	10.	da Silva MP, Cassim N, Ndlovu S, Marokane PS, Radebe M, Shapiro A, et al. More Than
440	101	a Decade of GeneXpert®Mycobacterium tuberculosis/Rifampicin (Ultra) Testing in
441		South Africa: Laboratory Insights from Twenty-Three Million Tests. Diagnostics (Basel)
442		[Internet]. 2023 Oct 1 [cited 2024 Feb 9];13(20). Available from:
443		https://pubmed.ncbi.nlm.nih.gov/37892074/
444	11.	Meyer-Rath G, Schnippel K, Long L, Macleod W, Sanne I. The Impact and Cost of Scal-
445	111	ing up GeneXpert MTB/RIF in South Africa. PLoS One [Internet]. 2012 [cited 2024 Feb
446		7];7(5):36966. Available from: www.plosone.org
447	12.	Cepheid. Xpert® MTB/RIF. Sunnyvale, California;
448	13.	Cepheid. Xpert® MTB/RIF Ultra [Internet]. Sunnyvale, California; [cited 2023 Sep 27].
440	10.	Available from:
450		https://www.cepheid.com/en-GB/tests/tb-emerging-infectious-diseases/xpert-mtb-rif-ul
450 451		tra.html
452	14.	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3:
452 453	14.	diagnosis-rapid diagnostics for tuberculosis detection,2021 update. World Health Or-
453 454		ganization [Internet]. 2021 [cited 2024 Feb 7];Module 3:1–164. Available from:
		https://www.who.int/publications/i/item/9789240029415
455 456	15.	Azman AS, Golub JE, Dowdy DW. How much is tuberculosis screening worth? Esti-
450 457	10.	mating the value of active case finding for tuberculosis in South Africa, China, and India.
458		BMC Med [Internet]. 2014 Oct 30 [cited 2024 Feb 7];12(1). Available from:
458 459		https://pubmed.ncbi.nlm.nih.gov/25358459/
	16.	Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, et al. Sustainable HIV
460	10.	treatment in Africa through viral-load-informed differentiated care. Nature [Internet].
461 462		2015 Dec 2 [cited 2024 Feb 9];528(7580):S68–76. Available from:
462 463		https://pubmed.ncbi.nlm.nih.gov/26633768/
463 464	17.	Nichols B, Phillips A. Viral Loads and DALYs averted. Email communication. 2023.
465	17.	Terris-Prestholt F, Boeras D, Ong JJ, Torres-Rueda S, Cassim N, Mbengue MAS, et al.
466	10.	The potential for quality assurance systems to save costs and lives: the case of early in-
467		fant diagnosis of HIV. Trop Med Int Health [Internet]. 2020 Oct 1 [cited 2024 Feb
468		9];25(10):1235–45. Available from: https://pubmed.ncbi.nlm.nih.gov/32737914/
469	19.	Haeri Mazanderani AF, Murray TY, Johnson LF, Ntloana M, Silere-Maqetseba T, Guo S,
470	17.	et al. Eliminating Vertical Transmission of HIV in South Africa: Establishing a Baseline
470		for the Global Alliance to End AIDS in Children. Diagnostics 2023, Vol 13, Page 2563
471 472		[Internet]. 2023 Aug 1 [cited 2024 Feb 9];13(15):2563. Available from:
		https://www.mdpi.com/2075-4418/13/15/2563/htm
473 474	20.	Sherman GG, Cooper PA, Coovadia AH, Puren AJ, Jones SA, Mokhachane M, et al.
474 475	<u>∠</u> 0,	Polymerase chain reaction for diagnosis of human immunodeficiency virus infection in
		infancy in low resource settings. Pediatric Infectious Disease Journal [Internet]. 2005
476		mancy in low resource settings, retraine intectious Disease journal [internet], 2000

477		[cited 2024 Mar 22];24(11):993–7. Available from:
478		https://journals.lww.com/pidj/fulltext/2005/11000/polymerase_chain_reaction_for_diag
479		nosis_of_human.14.aspx
480		21. Han AX, Girdwood SJ, Khan S, Sacks JA, Toporowski A, Huq N, et al. Strategies for
481		Using Antigen Rapid Diagnostic Tests to Reduce Transmission of Severe Acute Respir-
482		atory Syndrome Coronavirus 2 in Low- and Middle-Income Countries: A Mathematical
483		Modelling Study Applied to Zambia. Clin Infect Dis [Internet]. 2023 Feb 15 [cited 2024
484		Feb 9];76(4):620–30. Available from: https://pubmed.ncbi.nlm.nih.gov/36208211/
485		22. FIND. TIDES-C19: The Infectious Disease and Epidemic Simulation for COVID-19 [In-
486		ternet]. Economist Impact. 2022 [cited 2024 Feb 9]. Available from:
487		https://impact.economist.com/health/tides/covid-19/
488	23.	Lee J, Song JU. Diagnostic accuracy of the Cepheid Xpert Xpress and the Abbott ID NOW assay
489		for rapid detection of SARS-CoV-2: A systematic review and meta-analysis. J Med Virol [In-
490		ternet]. 2021 Jul 1 [cited 2024 Mar 22];93(7):4523–31. Available from:
491		https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26994
492	24.	Hans L, Cassim N, Sarang S, Hardie D, Ndlovu S, Venter WDF, et al. HIV Viral Load Testing in
493		the South African Public Health Setting in the Context of Evolving ART Guidelines and Ad-
494		vances in Technology, 2013–2022. Diagnostics 2023, Vol 13, Page 2731 [Internet]. 2023 Aug 22
495		[cited 2024 Feb 9];13(17):2731. Available from:
496		https://www.mdpi.com/2075-4418/13/17/2731/htm
497	25.	Scott LE, Hsiao NY, Dor G, Hans L, Marokane P, da Silva MP, et al. How South Africa Used
498		National Cycle Threshold (Ct) Values to Continuously Monitor SARS-CoV-2 Laboratory Test
499		Quality. Diagnostics 2023, Vol 13, Page 2554 [Internet]. 2023 Aug 1 [cited 2024 Feb
500		9];13(15):2554. Available from: https://www.mdpi.com/2075-4418/13/15/2554/htm
501	26.	Radebe L, Haeri Mazanderani A, Sherman GG. Indeterminate HIV PCR results within South
502		Africa's early infant diagnosis programme, 2010–2019. Clinical Microbiology and Infection.
503		2022 Apr 1;28(4):609.e7-609.e13.
504	27.	UNICEF. UNICEF Data - Country Profiles. 2022 [cited 2024 Feb 9]. South Africa (ZAF) - De-
505		mographics, Health & Infant Mortality. Available from: https://data.unicef.org/country/zaf/
506	28.	Exchange Rates UK. US Dollar to South African Rand Spot Exchange Rates for 2022 [Internet].
507		2022 [cited 2024 Mar 4]. Available from:
508		https://www.exchangerates.org.uk/USD-ZAR-spot-exchange-rates-history-2022.html
509	29.	Coetzee L, Hirasen K, Jamieson L, Evans D, Meyer-Rath G. Linganisa TB Cost Model, South
510		Africa. Johannesburg: Health Economics and Epidemiology Research Office, University of the
511		Witwatersrand; 2022.
512	30.	Meyer-Rath G, van Rensburg C, Chiu C, Leuner R, Jamieson L, Cohen S. The per-patient costs
513		of HIV services in South Africa: Systematic review and application in the South African HIV
514		Investment Case. PLoS One [Internet]. 2019 Feb 1 [cited 2024 Feb 23];14(2):e0210497. Available
515		from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210497
516	31.	Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, et al. Sustainable HIV Treatment
517		in Africa through Viral Load-Informed Differentiated Care. Nature [Internet]. 2015 Dec 12
518		[cited 2024 Mar 4];528(7580):S68. Available from: /pmc/articles/PMC4932825/
		-

519	32.	Ozawa S, Clark S, Portnoy A, Grewal S, Brenzel L, Walker DG. Return On Investment From
520		Childhood Immunization In Low- And Middle-Income Countries, 2011-20. Health Aff (Mill-
521		wood) [Internet]. 2016 [cited 2024 Feb 9];35(2):199–207. Available from:
522		https://pubmed.ncbi.nlm.nih.gov/26858370/
523	33.	Johns Hopkins University - International Vaccine Access Center (IVAC). Methodology Report:
524		Decade of Vaccines Economics (DOVE) Return on Investment Analysis. [Internet]. 2019 [cited
525		2024 Feb 9]. Available from: http://immunizationeconomics.org/dove-roi
526	34.	Sah P, Vilches TN, Moghadas SM, Pandey A, Gondi S, Schneider EC, et al. Return on Invest-
527		ment of the COVID-19 Vaccination Campaign in New York City. JAMA Netw Open [Internet].
528		2022 Nov 1 [cited 2024 Feb 9];5(11):e2243127. Available from:
529		https://pubmed.ncbi.nlm.nih.gov/36409495/
530	35.	Lamontagne E, Over M, Stover J. The economic returns of ending the AIDS epidemic as a pub-
531		lic health threat. Health Policy (New York). 2019 Jan 1;123(1):104–8.
532	36.	UNAIDS. Fast-Track: Ending the AIDS epidemic by 2030 [Internet]. Geneva; 2014 [cited 2024
533		Feb9].Availablefrom:
534		https://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf
535	37.	National Institute of Communicable Diseases. National Surveillance Dashboards. 2022 [cited
536		2024 Mar 5]. Microbiologically Confirmed Pulmonary TB - South Africa. Available from:
537		https://mstrweb.nicd.ac.za/MicroStrategy/asp/Main.aspx?Server=NICDSANDMSTRI01&Proje
538		ct=Surveillance&Port=0&evt=2048001&src=Main.aspx.2048001&documentID=4236FF364F683E
539		2F257DA5AC647F5BA6¤tViewMedia=1&visMode=0
540	38.	Stop TB Partnership. World TB Day Theme. 2022 [cited 2024 Feb 9]. Invest to End TB. Save
541		Lives. Available from: https://www.stoptb.org/news/invest-to-end-tb-save-lives
542		39. Mzembe T, Lessells R, Karat AS, Randera-Rees S, Edwards A, Khan P, et al. Prevalence
543		and Risk Factors for Mycobacterium tuberculosis Infection Among Adolescents in Rural
544		South Africa. Open Forum Infect Dis [Internet]. 2021 Jan 1 [cited 2024 Feb 9];8(1).
545		Available from: /pmc/articles/PMC7814392/
546		

547